依据PSA密度、4Kscore和风险计算器避免不必要的前列腺MRI和活检:MRI的阴性及阳性预测值
该研究纳入266例初次活检、临床怀疑前列腺癌的男性,评估mpMRI、4Kscore、PSAd及ERSPC-RC对避免不必要检查和活检的价值。对于PI-RADS 1-2病灶,低/中4Kscore风险、PSAd<0.10ng/ml/cm3或ERSPC-RC<2%的阴性预测值高;对于PI-RADS 3-5病灶,上述低风险组的阳性预测值低。最佳策略为先4Kscore后mpMRI再活检可漏诊2.7%临床显著前列腺癌并避免34.2%活检。
要点
- PI-RADS 1-2且PSAd<0.10ng/ml/cm3或ERSPC-RC<2%时阴性预测值达98.7%。
- PI-RADS 3-5且低4Kscore风险时阳性预测值为0%。
- 先4Kscore后mpMRI再活检策略可漏诊2.7%临床显著前列腺癌,避免34.2%活检。
核心结论
- 结合临床风险筛查工具(如4Kscore、PSAd、ERSPC-RC)解读mpMRI结果有助于避免不必要的前列腺活检和诊断误差。
研究设计与样本
- 前瞻性评估266例初次活检、临床怀疑前列腺癌的男性,均接受mpMRI、4Kscore检测和前列腺活检,并计算PSAd和ERSPC-RC。
主要发现
- PI-RADS 1-2病灶中,低/中4Kscore风险的阴性预测值分别为96.9%和97.1%,PSAd<0.10ng/ml/cm3为98.7%,ERSPC-RC<2%为98.7%。
- PI-RADS 3-5病灶中,低4Kscore风险的阳性预测值为0%,PSAd<0.10ng/ml/cm3为13.2%,ERSPC-RC<2%为12.3%。
- 先4Kscore(>7.5%者行mpMRI,mpMRI阳性或4Kscore≥18%者活检)策略漏诊2.7%(2/74)临床显著前列腺癌,避免34.2%活检。
- 先mpMRI(阴性者若4Kscore≥18%或PSAd≥0.10ng/ml/cm3则活检)策略漏诊2.7%(2/74)或1.3%(1/74),避免25.2%或28.1%活检。
关键数值与推荐
- PI-RADS 1-2且PSAd<0.10ng/ml/cm3或ERSPC-RC<2%时阴性预测值98.7%。
- PI-RADS 3-5且低4Kscore风险时阳性预测值0%。
- 最佳活检策略:初始4Kscore>7.5%行mpMRI,若mpMRI阳性(PI-RADS 3-5)或4Kscore≥18%则活检。
临床怎么用
- 对临床怀疑前列腺癌的初次活检患者,可先检测4Kscore,仅高风险者行mpMRI,结合PSAd和ERSPC-RC决定是否活检。
- 解读mpMRI时应结合临床风险筛查工具,以降低不必要的检查和诊断误差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2019 European Association of Urology guidelines recommend multiparametric magnetic resonance imaging (mpMRI) for biopsy-naïve patients with clinical suspicion of prostate cancer (PC) and avoiding biopsy in patients with negative mpMRI and low clinical suspicion. However, consensus on the optimal definition of low clinical suspicion is lacking. We evaluated 266 biopsy-naïve patients who underwent mpMRI, the 4Kscore test, and prostate biopsy to define the best strategy to avoid unnecessary testing and biopsies. The European Randomized Study of Screening for Prostate Cancer risk calculator (ERSPC-RC) and prostate-specific antigen density (PSAd) were also considered. For men with Prostate Imaging-Reporting and Data System v2.0 (PI-RADS) 12 lesions, the highest negative predictive value was observed for those with low or intermediate 4Kscore risk (96.9% and 97.1%), PSAd <0.10ng/ml/cm3 (98.7%), and ERSPC-RC <2% (98.7%). For men with PI-RADS 35 lesions the lowest positive predictive value was observed for those with low 4Kscore risk (0%), PSAd <0.10ng/ml/cm3 (13.2%), and ERSPC-RC <2% (12.3%). The best biopsy strategy was an initial 4Kscore followed by mpMRI if the 4Kscore was>7.5% and a subsequent biopsy if the mpMRI was positive (PI-RADS 35) or the 4Kscore was 18%. This would result in missing 2.7% (2/74) of clinically significant PCs (csPCs) and avoiding 34.2% of biopsies. Initial mpMRI followed by biopsy for negative mpMRI (PI-RADS 12) if the 4Kscore was 18% or PSAd was 0.10ng/ml/cm3 resulted in a similar percentage of csPC missed (2.7% [2/74] and 1.3% [1/74]) but slightly fewer biopsies avoided (25.2% and 28.1%). Physicians should consider clinical risk screening tools when ordering and interpreting mpMRI results to avoid unnecessary testing and diagnostic errors. PATIENT SUMMARY: Performing the 4Kscore test in conjunction with multiparametric magnetic resonance imaging for men with a clinical suspicion of prostate cancer may help to reduce unnecessary biopsies.
引用
- Falagario UG, Martini A, Wajswol E, et al. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators. Eur Urol Oncol. 2019. PMID: 31548130. doi:10.1016/j.euo.2019.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。